IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors

IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as well as other existing investors. IsoPlexis will use the proceeds from this financing to expand its global commercial and R D teams, increase operational capacity to satisfy growing demand, and accelerate its next generation single-cell biology product development roadmap. About IsoPlexis IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in-vivo biology and develop more precise and personalized therapies. Our integrated systems – named as a top innovation or design by the Scientist Magazine, Fierce, BIG Innovation and Red Dot, among others – are used globally to advance the field of single-cell biology into new 'omic possibilities as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including 15 of the top 15 global pharmaceutical companies and by approximately 45% of comprehensive cancer centers. Visit http://www.isoplexis.com to learn more.
（以上内容由医药魔方AI生成）